Novartis | NOVN - Cash And Equivalent

Stock Price
115.90
Daily Change
2.56 2.26%
Monthly
-4.10%
Yearly
23.02%
Q2 Forecast
111.47

Novartis reported $11.44B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Alcon AG USD 1.5B 90M Sep/2025
Almirall EUR 337.77M 14.83M Dec/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
Autolus Therapeutics Ltd USD 104.13M 18.01M Dec/2025
Bayer EUR 5.9B 1.34B Sep/2025
Biogen USD 3.38B 374.2M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
Fresenius EUR 1.23B 1.16B Jun/2025
Fresenius Medical Care EUR 1.58B 326.57M Dec/2025
Galapagos EUR 87.87M 23.41M Dec/2025
Genmab DKK 1.72B 46M Dec/2025
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 801M 242.31M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
J&J USD 21.69B 1.98B Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.25B 1.08B Sep/2025
Merck USD 14.57B 3.6B Dec/2025
Novartis USD 11.44B 1.88B Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Orion EUR 160.9M 63.3M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
Philips EUR 1.91B 90M Sep/2025
Recordati EUR 471.46M 129.91M Sep/2025
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024